

PODD[®] PARTNERSHIP OPPORTUNITIES IN DRUG DELIVERY

2025 Event Highlights



INSIDE THIS ISSUE

| Topics & Who Covered Them
| Photographs From the Event

| PODD Reviews
| Next Year's Dates

Welcome

We are pleased to provide a summary of the highlights from the 15th annual PODD: Partnership Opportunities in Drug Delivery conference, held October 27-28, 2025, in Boston, MA. We had a record-breaking attendance with over **1,000** delegates generating a wonderful energy in the sessions, the partnering and exhibit hall. Many thanks to all who participated.

Day One began with the **Opening Keynote** where Dr Lotte Bjerre Knudsen, Chief Scientific Advisor, Novo Nordisk, presented on clinical data from GLP-1 Receptor Agonists, mechanism of action learnings, new insights and where drug delivery can improve their efficacy. For the **Annual Keynote Fireside Discussion**, Dr Robert Langer was joined by Dr Lotte Bjerre Knudsen about going beyond single digit oral bioavailability for peptides, brain delivery, how they think about IP and being scientifically courageous. Roche's Dr Beate Bittner spoke about **market trends**, drug approval highlights, drug delivery partnerships and highlighted therapeutic areas in her **Industry Overview** on the 2025 Drug Delivery Landscape.

Day Two began with **Patient Keynote**, Jimi Olaghere, who spoke about how a CRISPR-based therapy changed his life with sickle cell disease and how the industry can better enable wider access to these life-changing medicines.

Zeitgeist presenter, Dr Mansoor Amiji, PhD, University Distinguished Professor, Northeastern University, discussed **Endogenous Targeted Delivery** Strategies to **Advance Nucleic Acid Therapeutics**

Across the two days, there were **panel discussions** on:

- Partnering to Advance Drug Delivery Innovation
- Payer Perspectives on Drug Delivery
- Beyond LNPs: Delivering Genetic Medicines with Novel Vehicles
- Physical and Formulation Approaches for Brain Delivery
- Expanding Transdermal Delivery Opportunities
- Establishing a Regulatory Framework for Global Combination Device Development
- Advances and Opportunities in Dual Chamber Injectables
- Advances in Payload Delivery and Drug Conjugation and Bioconjugation
- Enabling At-Home Delivery of Vaccines
- Achieving Effective Manufacturing Scaleup for Clinical and Commercial Success
- Using Digital Technologies to Enhance Patient Experience and Better Manage Supply Chain
- Platform Approaches to Streamline Combination Product Development
- The Shift from IV to SC Delivery: Patient and Provider Perspectives
- Novel Approaches to Achieve Tissue-Specific Targeting for Nucleic Acid Therapeutics
- Drug Delivery in the Golden Age of Peptides and Biologics: Novel Approaches for Oral Delivery
- New Progress in Ophthalmic Delivery
- Ensuring Sustainability Throughout Drug and Device Development
- Challenges and Opportunities in Delivering Hyperconcentrated Formulations
- Accomplishing Sustained Release and Long Acting Delivery
- Respiratory Devices and Inhaled Biologics
- Utilizing AI to Facilitate Combination Product Development
- Novel Approaches to Deliver Large Volume Therapies

Across multiple tracks, PODD speakers presented **case studies** and thought-provoking presentations on:

- Injectable Formulations & Technologies
- Cell, Gene & Novel Biologics Delivery
- Novel Devices: Self-Injectables, Wearables & Connected Devices
- Novel Non-Injectable Technologies
- Novel Materials & Excipient Innovation
- Novel Device Technologies
- Novel Injectable and Non-Injectable Technologies
- Self-Injection Devices, Syringes, Primary Container & Packaging Solutions

Enjoy this special summary. As always, the PODD website provides year round editorial, podcasts and webinars. We have exciting news for 2026. PODD is now part of Fierce Life Sciences. Combining our resources allows for greater market reach, more networking and partnering. A big thank you to everyone who participated in this year's PODD.

Sincerely,
The PODD team,

Andrew Goldstein
PODD Conference Producer

Valerie Bowling
Executive Director

Bre Bugbee-Barrett
*Senior Conference & Multimedia
Marketing Manager*

Nicolette Angelo
*Lead Meeting Planner &
Conference Success Manager*

Alyssa Willeford
Senior Client Success Coordinator

Licelle Yuzon
Web & Graphics Associate

Meredith Sands
Executive Director, Strategic Partnerships

Shelby Casabura
*Strategic Partnerships &
Business Development Manager*

Michelle McDermott
Senior Drug Delivery Advisor

Libby Samolsky
Meeting Planning & Client Success Associate

*Nano*ImproveTM your drug performance

Chief Commercial Officer, Christian Jones, will co-present with Dr. Yumiko Mizuno, Head of Plasma-Derived Therapies Drug Product Development, Takeda, on:

“Delivering Value for Patients Through Nanoforming in Plasma Derived Therapies”

Monday, October 27, 2025 | 12:10 PM – 12:30 PM

Deputy CCO, Sr. VP Business Development, Sergie Letser, will join an expert panel discussion, moderated by Dr. Stephanie Reed, AstraZeneca, on:

“Challenges and Opportunities in Delivering Hyperconcentrated Formulations”

Tuesday, October 28, 2025 | 04:05 PM – 04:35 PM

info@nanoform.com
nanoform.com



Photo Gallery

For more photos, click [here](#)



Photo Gallery

For more photos, click [here](#)



Photo Gallery

For more photos, click [here](#)



PODD Speaking Faculty Shines

Keynotes

- Opening Keynote with Novo Nordisk's Chief Scientific Advisor Who Drove the Development of GLP-1 Drugs for Obesity: **Lotte Bjerre Knudsen, DMSc**, Chief Scientific Advisor, Novo Nordisk
- Innovation Leadership Keynote Fireside Discussion: **Robert Langer, PhD**, David H Koch Professor, MIT, with **Lotte Bjerre Knudsen, DMSc**, Chief Scientific Advisor, Novo Nordisk
- Patient Keynote: How a CRISPR-Based Therapy Changed Jimi Olaghere's Life with SCD: **Jimi Olaghere**, Patient Advocate, with **Sherri Biondi, PhD**, Executive Director & Head of Device Development, AstraZeneca
- Zeitgeist Presentation: Endogenous Targeted Delivery Strategies to Advance Nucleic Acid Therapeutics: **Mansoor Amiji, PhD**, University Distinguished Professor, Northeastern University

Conference Co-Chairs

- **Clare Beddoes, PhD**, Head of Drug Delivery, Cambridge Design Partnership
- **Sherri Biondi, PhD**, Executive Director & Head of Device Development
- **Beate Bittner, PhD**, Head Product Optimization, Roche

Track Chairs

- **Manish Gupta, PhD**, Portfolio & Technology Development, Vaccines, GSK
- **Russell Johnson, PhD**, Head of Delivery Sciences, Moderna
- **Ulrich Brüggemann**, Lead Advanced Drug Delivery Technical Development, Takeda
- **Parthiban Rajasekaran, DVM, PhD**, Innovation Lead, Sanofi
- **Liping Zhou, PhD**, Senior Director, Advanced Drug Delivery, AstraZeneca
- **F Javier Muñoz, PhD, MBA**, Technology Evaluation Leader, F Hoffmann-La Roche
- **Junwei Li, PhD, MBA**, Innovation Manager, Novo Nordisk
- **Scott Gibson**, Director, Global Operations Leadership, Obesity & Related Conditions, Amgen
- **Jill Steinbach-Rankins, PhD**, Senior Associate Director, Innovation Technology, Boehringer Ingelheim
- **Srini Sridharan, PhD**, Executive Director, Drug Delivery & Product Integration, Bristol Myers Squibb
- **Lipa Shah, PhD**, Director, Science & Technology, Drug Development/Pharmaceutical Development
- **Bryan Dillon**, External Manufacturing Operations Lead, UCB
- **Roger Liu, MEng, MBA**, Director, Combination Product Development, AbbVie
- **Ana Gomes dos Santos, PhD**, Director of Pharm Sci External Evaluations, AstraZeneca
- **Advait Badkar, PhD**, Executive Director - Drug Product Design & Development and Head of Nanoparticle Development, Pfizer
- **Theresa Scheuble**, Head, Enterprise Design & Innovation, Johnson & Johnson
- **Alasdair Young, BEng, MPhil**, Senior Director - Device Engineering, Gilead Sciences

Roche's Industry Overview on the Drug Delivery Landscape 2025

- **Beate Bittner, PhD**, Head Product Optimization, Roche

PODD Speaking Faculty Shines

What's So Special About Specialty Delivery

- **Clare Beddoes, PhD**, Head of Drug Delivery, Cambridge Design Partnership

A Breath of Opportunities: The Future of Inhaled Biologics

- **Mireia Puig-Sellart, PharmD, PhD**, Manager, Pharmaceutical Development, Phillips Medisize

15th Annual Pharma Company Spotlights

- **Mateja Kramer, PhD**, Global Head of Innovation, Novartis
- **Nicholas Schill, PhD**, Senior Director, Landscaping & Platform Definition, Device & Combination Product Development, AbbVie
- **Monica Swinney, PhD**, Senior Director, Innovation & New Product Planning, Gilead Sciences

Emerging Design Space Requirements in High-Dose Drug Development Pipeline: Dynamics, Challenges and Potential Technology Pathways

- **Beth McBride DiLauri**, Director, Global Marketing, BD Medical - Pharmaceutical Systems

Partnering to Advance Drug Delivery Innovation

- **Ester Caffarel-Salvador, PhD**, Director, Strategic Innovation, Chiesi USA
- **Annette Bak, PhD, MBA**, Head of Advanced Drug Delivery, AstraZeneca
- **Sean Bedingfield, PhD**, R&D Director - Genetic Medicine, Eli Lilly and Company
- **Jaymin Shah, PhD**, Senior Research Fellow & Head of Biopharmaceutics, Pfizer
- **Rashmi Thakur**, Director, Portfolio Strategy & Integration, Bristol Myers Squibb

Delivering Value for Patients Through Nanoforming in Plasma-Derived Therapies

- **Christian Jones**, CCO, Nanoform
- **Yumiko Mizuno, PhD**, Head of Plasma-Derived Therapies, Drug Product Development, Takeda Pharmaceuticals

“First time attending PODD and it truly lived up to its name - great focused partnering conference on all things drug delivery bringing together industry leaders and new technologies.”

Sebastien Latapie, Avant Bio

PODD Speaking Faculty Shines

1A: Injectable Formulations & Technologies, Part 1

- **Andreas Zumbuehl, PhD**, Scientific Specialist, InnoMedica
- **Anya Harry, MD, PhD**, CMO, VP, Head of Applied Research & Clinical Affairs, West Pharmaceutical Services
- **Okke Franssen, PhD**, Head of Nanomi, Nanomi a Lupin Group Company
- **Colin Spencer**, Head of Technology Transfer, Project Manager, Oakwood Labs
- **Nicolas Bralet**, Associate Business Director, Biologics PFS, BD Medical - Pharmaceutical Systems
- **Morgan Fox, MSE**, Senior Manager, Sales, Corbion
- **Rob Steendam, PhD**, CTO, InnoCore Pharmaceuticals
- **David Westberg**, CEO, Nanexa AB
- **Lukasz Koroniak, PhD**, Global Biomaterial Director Drug Delivery Solutions, dsm-firmenich
- **Wendy Naimark, PhD**, CTO & Co-Founder, Ripple Therapeutics

2A: Cell, Gene & Novel Biologics Delivery

- **Svilen Savov, PhD**, Device Development Lead, TTP: Technology and Product Development
- **Tony Duong, PhD**, Lead Drug Delivery Scientist, Battelle
- **Sho Ueno**, Research Scientist, NOF CORPORATION
- **Shaukat Ali, PhD**, Senior Director, Scientific Affairs & Technical Marketing, Ascendia Pharmaceutical Solutions
- **Saudat Fadeyi, PhD, MBA**, Head of Business Development & Strategy, Samyang
- **Brian Ginn, PhD**, Manager, Biomaterials Research, Secant Group
- **Philip Sheridan, PhD**, Senior Director, Business Development, Nitto BioPharma
- **Andreja Gramc Livk**, Head of Process Analytics, Sartorius BIA Separations
- **Wouter Latour, MD, MBA**, CEO, PharmaJet
- **Sam Barker, PhD**, CBO, ViaNautis

3A: Novel Devices: Self-Injectables, Wearables & Connected Devices

- **Amir Genosar**, CEO, Aktiv Medical Systems
- **Greg Panebianco**, Senior Director of Engineering & Customer Success, Flex
- **Fran Pencliffe, MEng**, Healthcare Device Engineer, Cambridge Design Partnership
- **Farid Seddighi**, Head of Technology & Operations, Haselmeier, a medmix Brand
- **Matthew Parker**, Device Innovation Lead, TTP: Technology and Product Development
- **Ilan Shopen**, Director of Marketing and Business Development, E3D – Elcam Drug Delivery Devices
- **Pete Evans**, Director of Device Development, SMC Ltd
- **Asmita Khanolkar**, Senior Director, SMC, Ltd
- **Andrew Schaefer**, Program Manager, Congruence Medical Solutions
- **Konrad Kauper**, VP, Neurotech
- **Claire Young**, Senior Human Factors Consultant, Team Consulting
- **Peter Stebbins**, VP, Program & Business Development, Satio

PODD Speaking Faculty Shines

4A: Novel Non-Injectable Technologies

- **TR Thirucote, PhD**, Chairman & CEO, TesoRX
- **Jose Lagaron, PhD**, CEO/CSO, BioNanoPharma
- **Yngve Mikkelsen, MD**, CMO, AlgiPharma
- **Chris Vernall**, EVP, Business Development, HCmed Innovations Co, Ltd
- **Matt Lanchantin**, Head of Corporate Development, Syntis Bio
- **Jatin Sood, PhD**, Group Leader - Formulation R&D, ARx LLC
- **Timothy Tracy, PhD**, Senior Advisor, Triastek
- **Terrence Tormey**, Director, Business Development, Transdermal Specialties Global
- **Jake Lombardo**, CEO, Anodyne Nanotech
- **Susan Conroy**, CEO, Therakind

5A: Novel Materials & Excipient Innovation

- **Chun Wang, PhD**, CSO, Trekka Therapeutics
- **Thomas Tice**, Senior Director, Strategic & Technical Marketing, Evonik
- **Marly Bastiaansen**, Business Unit Manager, Biopharma & Inhalation, DFE Pharma
- **Rigwed Tatu, PhD**, Extractables & Leachables Program Lead, PSN Labs
- **Pieter Muntendam, MD**, President & CEO, SQ Innovation, Inc
- **Charles Fortier, PhD**, Expert Researcher in Drug Product Development, Adocia
- **Anil Diwan, PhD**, President & Executive Chairman, Nanoviricides
- **James Baxter, MSM**, Technical Business Development Manager, Lubrizol
- **Eunice Costa**, R&D Fellow, Program Director for Respiratory & New Modalities, Hovione
- **Thomas Kelleher, PhD**, CEO, Xylome

1B: Injectable Formulations & Technologies, Part 2

- **Juhan Lee, PhD**, Director, G2GBIO
- **Bryan Mazlish**, CEO, Surf Bio
- **Brian Doherty, PhD**, Senior Manager, Business Development, Lipoid
- **David Opie, PhD**, SVP of R&D, Noxilizer
- **Brad Minrovic, PhD**, Technical Sales Account Manager, Pharmaceutical Injectables, Ashland
- **Andrei Yosef, PhD**, President, LTS Device Technologies, LTS Lohmann
- **Teresita Pileggi**, Principal Human Factors Engineer, Design Science
- **Frederic Dargelas, PhD, MBA**, CCO, DelSiTech
- **Michael Sailor, PhD**, CSO, SiCare Bio

“Thank you to organizers, and the vibrant community at PODD for discussions and flawless coordination.”

Mateja Kramer, Novartis

PODD Speaking Faculty Shines

2B: Cell, Gene & Novel Biologics Delivery

- **Shira Orr, PhD**, Co-Founder & CEO, Envoya
- **Julie Devalliere, PhD**, Sr Manager, Biology Team, Nanobiotix
- **Patrick Ruane, PhD**, COO, Re-Vana Therapeutics
- **John Black, MEd**, CEO, Vitranu
- **Clay Larsen**, President & CEO, Vesselon, Inc
- **Brent Hahn**, CEO, Gram Medical
- **John Reid**, CBO, QurCan Therapeutics

3B: Novel Injectable & Non-Injectable Technologies

- **Jack Auld**, Co-CEO & Co-Founder, Altaviz
- **Reenal Gandhi**, Director, Business Development, Aptar Pharma
- **Erik Ferrier**, Device & Combination Products, Device & Packaging Technology, Manufacturing Sciences & Technology, Bristol Myers Squibb
- **Bill Welch**, Executive Director Market Development, PCI Pharma Services
- **Brent Rutland, PhD**, VP of Global Medical & Clinical Affairs, KORU Medical Systems
- **Yuki Takeuchi**, Global Product Manager for the PLA/JEX Ready-To-Fill Syringe Platform, Terumo
- **Micahel Travanty**, VP, Product Development Engineering, Halozyme
- **Deep Bhattacharya, PhD**, Principal Scientist, Pfizer
- **Tom Oakley**, Board Member & VP Design & Development, Sanner Group
- **Vijay Kudchadkar**, Director of Plastics & Sales Engineering, Nissha Medical Technologies - Isometric Micro Molding
- **Victor Mishin**, Scientist II, Translational Product Development, Secant Group
- **Steve Duddy**, Co-Founder & CEO, RheoTek Medical Inc.

4B: Novel Injectable & Non-Injectable Technologies

- **Dan Mallon**, SVP, Corporate Development, PharmaJet
- **Carla Castellar, PhD**, Scientific Manager, Nanomol, Technologies
- **Breck Petrillo**, Sr Director, Commercial Business, Development, Battelle
- **Jeff Haley, PhD**, Global Technology Manager: VitalDose® & Ateva® Polymers, Celanese
- **Karthik Raman, PhD**, CEO, Persist AI Formulations Corp
- **James Mainwaring**, Strategy Consultant, Zephyrus Innovations
- **Matthew Hancock, PhD**, Principal, Veryst Engineering
- **Sean Teller, PhD**, Principal, Veryst Engineering
- **Chan Hee Chon, PhD**, CTO, Inventage Lab
- **Kamu Konduri, MD**, Chair, VGSK Technologies, Inc

PODD Speaking Faculty Shines

5B: Self-Injection Devices, Syringes, Primary Container & Packaging Solutions

- **David DeSalvo**, VP, Combination Product Development, Kindeva
- **Laxman Halleppanavar**, Head of Portfolio Strategy & Management, Credence MedSystems, Inc.
- **Alessio Bonati**, Director Alba & Nexa Flex Programs, Stevanato Group
- **Jonathan Amaya-Hodges**, Consulting Director, Suttons Creek, a BlueRidge Life Sciences company
- **Masashi Miura**, Researcher, Mitsubishi Gas Chemical
- **Bernd Mahlmann, MBA**, Associate Director, Account & Business Development, Ypsomed
- **Daniele Tartini**, Senior Business Development Manager – Glass Syringes, Schott North America
- **Josh Hartl**, Partner & Senior Industrial Designer, Key Tech
- **Oliver Eden, MEng (Hons), PhD**, Senior Business Unit Director, Jabil Healthcare
- **Hector Gonzalez**, Director of Sales, Weiss-Aug
- **Stephen Harhen, PhD**, CTO, RxBandz

Payer Perspective on Drug Delivery

- **Mark Simon, MBA**, Strategic Advisor, Sun Pharmaceuticals Industries, Ltd.
- **Michael Sherman, MD, MBA, MS**, Principal, Sherman Healthcare Solutions, LLC
- **Lambert van der Walde, MBA**, SVP & Executive Director, Center for Health Care Research, UnitedHealth Group

Drug Delivery Pipeline & Technologies, a Year in Review

- **Kurt Sedo**, Executive Editor, PharmaCircle

Pushing the Limits: What It Will Take to Inject More

- **Alex Lyness, PhD**, Head of Applied Research & Innovation Strategy, SHL Medical

Enabling a Breakthrough in Ophthalmology: A Case Study in Collaboration between a Biotech and Device Manufacturer on a Novel Drug Delivery System

- **Mark DeStefano**, Director of Global Technology Innovation, CPD R&D, Teva Pharmaceuticals
- **Ashwin Agarwal, MBA**, CFO, Azura Ophthalmics
- **John Merhige**, CCO, Credence MedSystems

Dealmaking Fireside Discussion: Bringing Drug Delivery to the Front

- **Michael Cucolo, MS**, Executive Director, Business Development Transactions, Bristol Myers Squibb
- **Anand Subramony, PhD**, VP, Drug Delivery, Device, Connected Solutions & Innovation, Eli Lilly and Company

PODD Speaking Faculty Shines

The Win-Win-Win Partnership Model: Accelerating Combination Product Success for Emerging Biotech

- **Ning Yu, PhD, MBA**, VP, Device & Combination Product, Astria Therapeutics
- **Lilli Zakarija, MBA**, President / Co-Founder, EdgeOne Medical

PODD Annual Soapbox Presentations, Hosted by Pfizer, Host

- **Patrick Lim Soo, PhD**, Associate Research Fellow, Pharmaceutical Research & Development, Pfizer

PODD Annual Soapbox Presentations, Hosted by Pfizer

- **Idicula Mathew**, CEO, Hera Health Solutions
- **Tamás Kiss, PhD**, Formulation Project Manager, CarboHyde
- **Patrick Fitzgerald, MD**, CEO, Pituvia
- **Shawn Marcell**, Executive Chairman, Sempresto
- **Stephen Cohen, MD, FACS**, Co-CEO & Co-Founder, Akysso Therapeutics
- **Sherwood Yao**, CEO & Co-Founder, Atom Bioworks
- **Sean Michael Carroll, PhD**, Director, Business Development, Manifold Bio
- **William Ferreira Andrén**, CEO, Aperia

Beyond LNPs: Delivering Genetic Medicines with Novel Vehicles

- **Sanyogitta Puri, PhD**, Sr Director, RNA & Gene Therapies - Non-Viral Delivery, Novo Nordisk
- **Vinu Krishnan, PhD**, Principal Research Scientist, CMC Formulation Development & Drug Delivery, AbbVie
- **Ruchi Shah, PhD**, Head US Drug Product, Vaccines Technical R&D, GSK
- **Anand Subramony, PhD**, VP, Drug Delivery, Device, Connected Solutions & Innovation, Eli Lilly and Company
- **Kanika Suri, PhD**, Scientist, Drug Product Development, CMC, Takeda Pharmaceuticals

Physical and Formulation Approaches for Brain Delivery

- **Hicham Majd, PhD**, Global Device & Packaging Innovation Lead, Novartis
- **Peter Åhnblad, MD**, Co-inventor, Co-Founder of HOGNE AB, HOGNE AB
- **Karla Sanchez, PhD**, CNS Drug Delivery Lead, Cambridge Design Partnership
- **Mansuo Shannon, PhD**, CSO, AskBio/Bayer

“Yet another successful PODD2025, the event keeps growing in scale and strives to connect the community of drug delivery professionals across all modalities and therapy areas.”

Sanyogitta Puri, Novo Nordisk

PODD Speaking Faculty Shines

Platform Approaches to Streamline Combination Product Development

- **Lindsey Crawford, PhD**, Senior Principal Scientist, Pfizer
- **Bradley Gould, MEng**, Director, Device & Combination Product Development, AbbVie
- **Shirish Ingawale, PhD**, Director, Device & Combination Product Development, Takeda Pharmaceuticals
- **Tim Quigg**, Development Director, Crux Product Design
- **Monica Swinney, PhD**, Senior Director, New Product Planning & Drug Delivery Innovation, Gilead Sciences

The Shift from IV to SC Delivery: Patient and Provider Perspectives

- **Charles Theuer, MD, PhD**, CMO, Halozyme
- **Cathleen Bergin, MSN, ANP**, Head of US Field Clinical Educator Team, argenx
- **Todd Kennedy**, Patient & Research Advocate, Lived-Experience Expert

LNP Delivery to Create In Vivo CAR-Monocytes Leads to Complete Depletion of B-Cells in NHPs

- **Shawn Davis, PhD**, CEO, Liberate Bio

One Device, 10-Year Life. A New Era in Drug Delivery

- **Ashley Hawson**, SVP Innovation & Operations, Cambridge Consultants
- **Elizabeth Proos**, VP, Product Development, Daré Bioscience

Combination Products & Platforms For 2030: Leveraging Today's 'Best-In-Class' Device Development Methodologies To Engineer Tomorrow's Blockbuster Devices

- **Tim Quigg**, Development Director, Crux Product Design

POZ™ + enFuse®: Combining Novel Drug and Device Platforms to Provide a Leap Forward in Patient-Centered Care

- **Matt Huddleston**, CCO, Enable Injections
- **Randall Moreadith, MD, PhD**, CDO, Serina Therapeutics

Novel Approaches to Achieve Precision Tissue Targeting for Nucleic Acid Therapeutics

- **Drew Applefield, PhD**, Former Director of Search & Evaluation, Platform Technologies, Sanofi
- **Allison Dane, PhD**, Senior Director, AskBio
- **Ketaki Deshmukh, PhD**, Senior Scientist, Non Viral Delivery, Novo Nordisk
- **Subhadeep Dutta, PhD**, Senior Scientist; Discovery Pharmaceutical Sciences, Merck Research Laboratories
- **Manmohan Singh, PhD**, CTO, Beam Therapeutics

PODD Speaking Faculty Shines

New Approaches for Expanding Transdermal Delivery Opportunities

- **Tycho Speaker, PhD**, Senior Principal Research Scientist, Combination Product Development & Drug Delivery, AbbVie
- **Rikhav Gala, PhD**, Group Lead, Senior Principal Scientist, Pfizer
- **Konstantinos Tzortzakis**, CBO, Anodyne Nanotech
- **Jatin Sood, PhD**, Group Leader - Formulation R&D, ARx LLC

Establishing a Regulatory Framework for Global Combination Device Development

- **E Guan, PhD**, Head of Injection Systems, Takeda Pharmaceuticals
- **Jonathan Amaya-Hodges**, Consulting Director, Suttons Creek, a BlueRidge Life Sciences company
- **Karen Lowitz, MS, MBA**, Associate Director, Regulatory, CMC Devices & Combination Products, Biogen

Advances and Opportunities in Dual Chamber Injectables

- **Joyce Zhao, PhD**, Director, Combination Product Device Development, Takeda Pharmaceuticals
- **Brent Buchine, PhD**, CBO, Windgap Medical
- **David DeSalvo**, VP of Combination Product Development, Kindeva
- **Dan Groszmann, PhD**, Director of Engineering, Amgen
- **Courtney Nicholas Sutton**, Head of Portfolio Strategy, SHL Medical

Advances in Payload Delivery and Drug Conjugation

- **Sudhakar Garad, PhD**, Global Head of Chemical & Pharmaceutical Profiling, Novartis
- **Mandana Borna, PhD**, Head of Oligonucleotide Drug Product Development, Biogen
- **Suman Luthra, PhD**, Director, Discovery Pharmaceutical Sciences, Merck Research Laboratories
- **Benjamin Smith, PhD**, Senior Director, Protein Science & Bioconjugation, Voyager Therapeutics
- **Stefan Yohe, PhD**, Associate Research Fellow, Pfizer

Enabling At-Home Delivery of Vaccines

- **Patrick Lim Soo, PhD**, Associate Research Fellow, Pharmaceutical Research & Development, Pfizer
- **Ana Cadete Pires, PharmD, PhD**, CMC Project Leader, mRNA Vaccines, Early Programs, Sanofi
- **Tom Lake, MBA**, CBO, Vaxxas
- **Duncan Paterson, CEng, MBA**, Senior Director, Device Development, AstraZeneca

Achieving Effective Manufacturing Scaleup for Clinical and Commercial Success

- **Kinsuk Shah, MSc, MBA**, SR AD, Combination Product Steward, Boehringer Ingelheim
- **Saran Baskaran, BSE, MEng**, Associate Director, R&D Combination Products, AstraZeneca
- **Ana Rusetski, MSc**, Senior Manager, Device & Combination Product Development, Astria Therapeutics
- **Ryan Swanson, PhD**, Director of Process Development, Lifecore Injectables CDMO

PODD Speaking Faculty Shines

Using Digital Technologies to Enhance Patient Experience and Better Manage Supply Chain

- **Ravi Kaushik, MBA**, VP, Global Head of Device & Digital Innovation & Product Strategy, PDT, Takeda Pharmaceuticals
- **Rebecca Ford, PMP**, VP, Strategic Development, Product Design & Engineering, Veranex
- **Junwei Li, PhD**, Innovation Manager, Novo Nordisk

Drug Delivery in the Golden Age of Peptides and Biologics: Novel Formulation Approaches for Oral Delivery

- **Sarah Tao, PhD**, Head of Search & Evaluation, Technology Platforms, Sanofi
- **Saadyah Averick, PhD**, Senior Director, Oral Delivery, Imagine Pharma
- **Stephen Buckley, PhD**, VP, Advanced Drug Delivery, Novo Nordisk
- **Riet Dams, PhD**, VP, Global Head Pharmaceutical Product Development & Supply, J&J Innovative Medicine
- **Thomas von Erlach, PhD**, CSO, Vivtex Corporation

New Progress in Ophthalmic Delivery

- **Shankar Swaminathan, PhD**, Team Lead, Drug Product Development, Astellas Institute for Regenerative Medicine, Astellas Pharma
- **Tim Carroll, MS, MBA**, Delivery Strategy & Surgeon Engagement, Genentech
- **Nathan Lockwood, PhD**, Director of Science & Technology, ProMed Pharma
- **Ruchi Thakkar, PhD**, Senior Scientist, Bristol Myers Squibb

Ensuring Sustainability Throughout Drug and Device Development

- **Ulrich Brüggemann**, Lead Advanced Drug Delivery Technical Development, Takeda Pharmaceuticals
- **Patrick Anquetil, PhD, MBA**, CEO, Portal Instruments
- **Andrea Casazza**, R&D Global Head of Technical Development, Chiesi
- **Charlie Dean**, Head of Sustainable Medical Technology, Cambridge Consultants
- **Smrithi Padmakumar, PhD**, Associate Principal Scientist, Merck Research Laboratories
- **Justin Schroeder, MBA**, Global VP of Technical Sales, PCI Pharma Services

Challenges and Opportunities in Delivering Hyperconcentrated Formulations

- **Stephanie Reed, PhD**, Director, Early Stage Formulation, Biopharmaceutical Development, AstraZeneca
- **Deep Bhattacharya, PhD**, Principal Scientist, Pfizer
- **Ryan Doxey**, VP, Tech Ops & CMC, Kymanox
- **Sergie Letser**, Deputy CCO & SVP Business Development USA, Nanoform

PODD Speaking Faculty Shines

Accomplishing Sustained Release and Long Acting Delivery

- **Tyler Novak, PhD**, Director of Drug Delivery Strategy & Innovation, Gilead Sciences
- **Christine Allen, PhD**, CEO & Co-founder, Intrepid Labs
- **Seth Forster, PhD**, Associate Principal Scientist, Merck Research Laboratories
- **Shrenik Mehta, MS, PhD**, Senior Principal Scientist, Genentech
- **Puneet Tyagi, PhD**, Associate Director, AstraZeneca

Respiratory Devices and Inhaled Biologics

- **Dan Deaton, MBA**, Executive Director Device Development & Innovation, AstraZeneca
- **Charles Potter, PhD**, Project Leader, Chiesi
- **Mireia Puig-Sellart, PharmD, PhD**, Manager, Pharmaceutical Development, Phillips Medisize
- **Philippe Rogueda, PhD, FRSC, CChem, CSci**, CBO, Merx Ltd

Utilizing AI to Facilitate Combination Product Development

- **Theresa Scheuble**, Head, Enterprise Design & Innovation, Johnson & Johnson
- **Fady Ibrahim, PhD**, Head of Drug Product Development & Biopharmaceutics, Sanofi
- **Ameya Phadke, PhD**, Senior Director, Non Pharma Solutions, Chiesi

Novel Approaches to Deliver Large Volume Therapies

- **Ravi Kaushik, MBA**, VP, Global Head of Device & Digital Innovation & Product Strategy, PDT, Takeda Pharmaceuticals
- **Chris Cooper, MEng**, Sr Device Engineer II, Gilead Sciences
- **Brent Rutland, PhD**, VP of Global Medical & Clinical Affairs, KORU Medical Systems
- **Amin Sedighiamiri, PhD**, Senior Director, Device Development & Technology, Merck Research Laboratories
- **Liat Shochat**, VP of Combination Product Development, EdgeOne Medical

“Reflecting on an inspiring experience at the PODD Conference on Drug Delivery!”

It was a pleasure to attend this year’s PODD conference, where innovation, collaboration, and sustainability in drug delivery were at the forefront of every discussion.”

Andrea Casazza, Chiesi

Thank You to the PODD 2025 Sponsoring Companies

Lead Sponsor



Featured Executive Sponsor



Executive Sponsors



Featured Associate Sponsor



Thank You to the PODD 2025 Sponsoring Companies

Associate Sponsors

ANODYNE
Nanotech

cambridge
consultants
Part of Cargene Invest

GSK

Halozyne

HOGNE

IDENTIV

intrepid

Kymanox
Your Life Science Solutions Partner
Bio | Pharma | Device | Combo

PA
Bringing
Ingenuity
to Life.

Pfizer

PHARMACIRCLE

Portal Instruments

SAMYANG
SINCE 1924


sanofi

Veranex

windgapmedical

Thank You to the PODD 2025 Sponsoring Companies

Technology Track Sponsors



Thank You to the PODD 2025 Sponsoring Companies

Technology Track Sponsors



Thank You to the PODD 2025 Sponsoring Companies

Exhibiting Sponsors




Thank You to the PODD 2025 Sponsoring Companies

Supporting Sponsors



Soapbox Sponsors



SAVE THE DATE

PODD[®] PARTNERSHIP OPPORTUNITIES IN DRUG DELIVERY

October 29–30, 2026

The Sheraton Boston
Boston, MA

**Annual Event
Digital Editorial
Year-Round Podcasts & Webcasts**

WWW.PODDCONFERENCE.COM

*For inquiries about speaking opportunities, topics or sponsorships,
email service@tcfillc.org*